アルツハイマー病診断の世界市場：洞察、競合情勢、市場予測：2030年

世界のアルツハイマー病（AD）診断の市場規模は、2024年から2030年までの予測期間中に10.97％のCAGRで拡大すると予測されています。アルツハイマー病（AD）診断市場は、アルツハイマー病（AD）診断薬に対する世界の規制承認の増加などの要因により、楽観的な市場成長を観察しています。さらに、事故や労働災害などによる頭部外傷の有病率の上昇や高齢者人口の増加は、アルツハイマー病の有病率を増加させ、それによって世界中のアルツハイマー病診断装置の需要を増加させます。加えて、新規バイオマーカーの研究開発の増加、市場における主要参入企業の存在、製品の上市と承認の増加なども、今後数年間でアルツハイマー病診断薬の必要性を生み出すとみられています。

アルツハイマー病（AD）診断市場を牽引する重要な側面の1つは、世界中で認知症の有病率が上昇していることです。アルツハイマー病は、記憶、思考、行動に影響を及ぼす認知症の一種です。したがって、認知症の有病率の増加はアルツハイマー病の有病率を増加させ、最終的にその診断装置の需要を増加させる。例えば、世界保健機関（WHO）の2022年の発表によると、世界中で約5,500万人が認知症であり、60％以上が低・中所得国に住んでいると結論付けられています。また、ほぼすべての国で人口に占める高齢者の割合が増加しており、この数は2030年には7,800万人、2050年には1億3,900万人に増加すると予想されています。

当レポートでは、世界のアルツハイマー病（AD）診断市場について調査し、市場の概要とともに、診断タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 アルツハイマー病（AD）診断市場レポートのイントロダクション

第2章 アルツハイマー病（AD）診断市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 アルツハイマー病（AD）診断市場の主な要因分析

• アルツハイマー病（AD）診断市場の促進要因
• アルツハイマー病（AD）診断市場の抑制要因と課題
• アルツハイマー病（AD）診断市場の機会

第5章 アルツハイマー病（AD）診断市場におけるポーターのファイブフォース分析

第6章 アルツハイマー病（AD）診断市場に対するCOVID-19の影響分析

第7章 アルツハイマー病（AD）診断市場の概要

• 診断タイプ別
• エンドユーザー別
• 地域別

第8章 アルツハイマー病（AD）診断市場の企業と製品プロファイル

• F. Hoffmann-La Roche Ltd.
• General Electric Company
• 23andMe, Inc.
• Lilly
• Fujirebio
• Siemens Medical Solutions USA, Inc.
• Diadem srl.
• Todos Medical
• DISCERN(TM)
• FUJIFILM Holdings America Corporation
• Koninklijke Philips N.V.
• CANON MEDICAL SYSTEMS EUROPE B.V.
• Shimzadu Corporation.
• Laboratory Corporation of America® Holdings
• Bruker
• Magnetica.
• IMRIS, Deerfield Imaging, Inc.
• MR Solutions
• Hyperfine, Inc.
• Neusoft Corporation

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1 Competitive Analysis
• Table 2 COVID-19 Impact Analysis on Alzheimer's Disease (AD) Diagnostic Market
• Table 3 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global (2021-2030)
• Table 4 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by Diagnostics Type (2021-2030)
• Table 5 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by End-user (2021-2030)
• Table 6 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by Geography (2021-2030)
• Table 7 Alzheimer's Disease (AD) Diagnostic Market Analysis in North America (2021-2030)
• Table 8 Alzheimer's Disease (AD) Diagnostic Market Analysis in North America by Country (2021-2030)
• Table 9 Alzheimer's Disease (AD) Diagnostic Market Analysis in the US (2021-2030)
• Table 10 Alzheimer's Disease (AD) Diagnostic Market Analysis in Canada (2021-2030)
• Table 11 Alzheimer's Disease (AD) Diagnostic Market Analysis in Mexico (2021-2030)
• Table 12 Alzheimer's Disease (AD) Diagnostic Market Analysis in Europe (2021-2030)
• Table 13 Alzheimer's Disease (AD) Diagnostic Market Analysis in Europe by Country (2021-2030)
• Table 14 Alzheimer's Disease (AD) Diagnostic Market Analysis in France (2021-2030)
• Table 15 Alzheimer's Disease (AD) Diagnostic Market Analysis in Germany (2021-2030)
• Table 16 Alzheimer's Disease (AD) Diagnostic Market Analysis in the UK (2021-2030)
• Table 17 Alzheimer's Disease (AD) Diagnostic Market Analysis in Italy (2021-2030)
• Table 18 Alzheimer's Disease (AD) Diagnostic Market Analysis in Spain (2021-2030)
• Table 19 Alzheimer's Disease (AD) Diagnostic Market Analysis in Russia (2021-2030)
• Table 20 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of Europe (2021-2030)
• Table 21 Alzheimer's Disease (AD) Diagnostic Market Analysis in Asia-Pacific (2021-2030)
• Table 22 Alzheimer's Disease (AD) Diagnostic Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 23 Alzheimer's Disease (AD) Diagnostic Market Analysis in China (2021-2030)
• Table 24 Alzheimer's Disease (AD) Diagnostic Market Analysis in Japan (2021-2030)
• Table 25 Alzheimer's Disease (AD) Diagnostic Market Analysis in India (2021-2030)
• Table 26 Alzheimer's Disease (AD) Diagnostic Market Analysis in Australia (2021-2030)
• Table 27 Alzheimer's Disease (AD) Diagnostic Market Analysis in South Korea (2021-2030)
• Table 28 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of Asia-Pacific (2021-2030)
• Table 29 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of World (2021-2030)
• Table 30 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of World by Region (2021-2030)
• Table 31 Alzheimer's Disease (AD) Diagnostic Market Analysis in the Middle East (2021-2030)
• Table 32 Alzheimer's Disease (AD) Diagnostic Market Analysis in Africa (2021-2030)
• Table 33 Alzheimer's Disease (AD) Diagnostic Market Analysis in South America (2021-2030)

List of Figures

• Figure 1 Competitive Analysis
• Figure 2 COVID-19 Impact Analysis on Alzheimer's Disease (AD) Diagnostic Market
• Figure 3 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global (2021-2030)
• Figure 4 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by Diagnostics Type (2021-2030)
• Figure 5 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by End-user (2021-2030)
• Figure 6 Alzheimer's Disease (AD) Diagnostic Market Analysis in Global by Geography (2021-2030)
• Figure 7 Alzheimer's Disease (AD) Diagnostic Market Analysis in North America (2021-2030)
• Figure 8 Alzheimer's Disease (AD) Diagnostic Market Analysis in North America by Country (2021-2030)
• Figure 9 Alzheimer's Disease (AD) Diagnostic Market Analysis in the US (2021-2030)
• Figure 10 Alzheimer's Disease (AD) Diagnostic Market Analysis in Canada (2021-2030)
• Figure 11 Alzheimer's Disease (AD) Diagnostic Market Analysis in Mexico (2021-2030)
• Figure 12 Alzheimer's Disease (AD) Diagnostic Market Analysis in Europe (2021-2030)
• Figure 13 Alzheimer's Disease (AD) Diagnostic Market Analysis in Europe by Country (2021-2030)
• Figure 14 Alzheimer's Disease (AD) Diagnostic Market Analysis in France (2021-2030)
• Figure 15 Alzheimer's Disease (AD) Diagnostic Market Analysis in Germany (2021-2030)
• Figure 16 Alzheimer's Disease (AD) Diagnostic Market Analysis in the UK (2021-2030)
• Figure 17 Alzheimer's Disease (AD) Diagnostic Market Analysis in Italy (2021-2030)
• Figure 18 Alzheimer's Disease (AD) Diagnostic Market Analysis in Spain (2021-2030)
• Figure 19 Alzheimer's Disease (AD) Diagnostic Market Analysis in Russia (2021-2030)
• Figure 20 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of Europe (2021-2030)
• Figure 21 Alzheimer's Disease (AD) Diagnostic Market Analysis in Asia-Pacific (2021-2030)
• Figure 22 Alzheimer's Disease (AD) Diagnostic Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 23 Alzheimer's Disease (AD) Diagnostic Market Analysis in China (2021-2030)
• Figure 24 Alzheimer's Disease (AD) Diagnostic Market Analysis in Japan (2021-2030)
• Figure 25 Alzheimer's Disease (AD) Diagnostic Market Analysis in India (2021-2030)
• Figure 26 Alzheimer's Disease (AD) Diagnostic Market Analysis in Australia (2021-2030)
• Figure 27 Alzheimer's Disease (AD) Diagnostic Market Analysis in South Korea (2021-2030)
• Figure 28 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of Asia-Pacific (2021-2030)
• Figure 29 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of World (2021-2030)
• Figure 30 Alzheimer's Disease (AD) Diagnostic Market Analysis in Rest of World by Region (2021-2030)
• Figure 31 Alzheimer's Disease (AD) Diagnostic Market Analysis in the Middle East (2021-2030)
• Figure 32 Alzheimer's Disease (AD) Diagnostic Market Analysis in Africa (2021-2030)
• Figure 33 Alzheimer's Disease (AD) Diagnostic Market Analysis in South America (2021-2030)
• Figure 34 Market Drivers
• Figure 35 Market Barriers
• Figure 36 Market Opportunities
• Figure 37 PORTER's Five Force Analysis

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET BY DIAGNOSTICS TYPE (BRAIN IMAGING [COMPUTED TOMOGRAPHY (CT), MAGNETIC RESONANCE IMAGING (MRI), POSITRON EMISSION TOMOGRAPHY (PET), AND OTHERS], GENETIC TESTING, BLOOD BASED TESTS, AND OTHERS), BY END-USER (HOSPITALS & CLINICS, DIAGNOSTIC CENTERS, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST till 2030 OWING TO THE INCREASING PREVALENCE AND INCIDENCE OF BRAIN INJURY, DIMENTIA, ALZHEIMER'S DISEASES, AND OTHERS, AND THE RISING BURDEN OF GERIATRIC POPULATION ACROSS THE GLOBE

The global Alzheimer's disease (AD) diagnostic market will grow at a CAGR of 10.97% during the forecast period from 2024 to 2030. The Alzheimer's disease (AD) diagnostic market is observing an optimistic market growth due to the factors such as rise in the regulatory approvals for Alzheimer's disease (AD) diagnostics across the globe. Further, the rising prevalence of head injuries owing to the accidents, workplace injuries, and others, and the rise in geriatric population will increase the prevalence of Alzheimer disease, thereby increasing the demand of the Alzheimer disease diagnostic devices across the globe. Additionally, the increasing research and development of novel biomarkers, presence of key players in the market, increasing product launches and approvals, and other will create a requisite for Alzheimer disease diagnostics in the upcoming years. Therefore, the market for Alzheimer's disease (AD) diagnostic is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET DYNAMICS:

One of the key aspect for driving the Alzheimer's disease (AD) diagnostic market is the rising prevalence of dementia across the globe. Alzheimer's is a type of dementia that affects memory, thinking and behavior. Thus, the increasing prevalence of dementia will increase the prevalence of Alzheimer disease, ultimately increasing the demand of its diagnostic devices. For instance, as per the World Health Organization (WHO) 2022, it was concluded that, worldwide, around 55 million people have dementia, with over 60% living in low- and middle-income countries. Also, as the proportion of older people in the population is increasing in nearly every country, this number is expected to rise to 78 million in 2030 and 139 million in 2050.

Furthermore, the rising regulatory approval for Alzheimer's disease (AD) diagnostic is expected to be another key factor for driving the Alzheimer's disease (AD) diagnostic market. Various product launches in this arena is several markets is driving the market growth.

For instance, in May 2022, Fujirebio Diagnostics, a global leader in the field of high quality in vitro diagnostics (IVD), received a green light from the US Food and Drug Administration (FDA), for its Lumipulse G B-Amyloid Ratio (1-42/1-40) test, which is designed for people who have cognitive impairment and are 55 years of age or older. The test was also designated as a breakthrough device, allowing it to pass through a quicker review procedure for goods that fill an unmet need.

Additionally, in February 2022, Diadem, pure diagnostic company, received CE-IVD mark for its non-invasive plasma-based AlzoSure Predict prognostic blood test which is used to detect Alzheimer's disease (AD) in the early stages.

Hence, the rising regulatory approvals for Alzheimer's disease (AD) diagnostic showing the need for diagnosis test owing to the rising prevalence of disease, thereby driving the Alzheimer's Disease (AD) Diagnostic overall market during the forecast period from 2024-2030.

Therefore, the factors stated above collectively will drive the overall for Alzheimer's disease (AD) diagnostic market during the forecast period from 2024-2030.

However, high cost of brain imaging, stigma and lack of awareness about the diagnosis of Alzheimer disease, and others may prove to be challenging factors for Alzheimer's disease (AD) diagnostic market growth.

The Alzheimer's disease (AD) diagnostic market was negatively impacted during the period of COVID- 19 pandemic owing to the decreased number of diagnostics tests due to the huge spread of COVID-19 infection across the globe. Further, in order to curb the spread of infection the government across the globe imposed strict lockdown rules, resulting in the shortage of supply chains, raw materials, and other resources in the market, leading to the decreased manufacturing of all the medical devices. Moreover, the patients and physicians postponed many elective surgeries, diagnostic tests, laboratory visits, and other healthcare facilities in order to stop the spread of the infection, thereby decreasing the number of in-patient visits in hospitals and clinics for diagnosis and treatment. However, vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape, which has initiated the process of resumption of regular healthcare services such as regular out-patients visits for treatments and diagnosis in hospitals, clinics, and laboratories, thereby bringing the demand for products on track in the alzheimer's disease (AD) diagnostic devices market.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET SEGMENT ANALYSIS:

Alzheimer's Disease (AD) Diagnostic Market by Diagnostics Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Others], Genetic Testing, Blood Based Tests, and Others), End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the diagnostics type segment of the Alzheimer's disease (AD) diagnostic market, the computer tomography (CT) segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the key benefits related to computer tomography (CT).

For instance, CT scans are used to detect the loss of brain mass linked to Alzheimer's Disease (AD) as well as they allows to take a detailed look inside the brain.

Further, it helps to collect multiple images of an area of the brain from different angles. Additionally, the scan helps to differentiate Alzheimer's disease (AD) from other types of dementia such as vascular dementia, mixed dementia, and others.

Moreover, increased launches of CT scans for brain imaging also increases the Alzheimer's disease (AD) diagnostics market demand. For instance, in May 2022, Koninklijke Philips N.V, a global leader in health technology, announced the launch of its pectral detector-based Spectral Computed Tomography (CT) 7500 system. The system delivers high quality spectral images for every patient including head scans and others.

Therefore, owing to the advantages and applications associated with CT segment along with the increasing product launches in the market, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global Alzheimer's disease (AD) diagnostic market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

Among all the regions, North America is expected to dominate the global medical device testing services in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to rising prevalence of head injuries, rise in geriatric population, rising product launches and approvals in the region, the presence of key market players in the region, and others will increase the demand of Alzheimer's disease (AD) diagnostic in the given forecast period.

For instance, according to the latest data available from the American Society for Biochemistry and Molecular Biology data published in the year 2023, in the United States, a brain injury occurs every nine seconds, resulting in more than 3.5 million incidents each year. Moreover, as per the above referenced source and statistics, about 2.8 million people suffers from traumatic brain injury (TBI) each year in the United States from which 2,80,000 resulting in hospitalizations. Therefore, rising cases for head injuries such as Traumatic Brain Injury (TBI) includes the high risk for developing the Alzheimer's disease.

Also, the increasing prevalence of Alzheimer disease in the United States will drive the market of the diagnostic devices. As per the data provided by the Alzheimer Association (2023), more than 6 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. The increasing prevalence of Alzheimer disease in the United States will increase the demand of its diagnostics devices, ultimately leading to the increased overall market growth.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the Alzheimer's disease (AD) diagnostic market.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET KEY PLAYERS:

Some of the key market players operating in the Alzheimer's Disease (AD) Diagnostic market includes F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN(TM), FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

In May 2022, the U.S. Food and Drug Administration today permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer's disease.

In May 2020, Lilly, a global health care leader, received US Food and Drug Administration (FDA) approval for its TAUVID(TM), a radioactive diagnostic agent for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being assessed for Alzheimer's disease (AD).

KEY TAKEAWAYS FROM THE ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET REPORT STUDY

• Market size analysis for current Alzheimer's Disease (AD) Diagnostic market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Alzheimer's disease (AD) Diagnostic market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Alzheimer's disease (AD) Diagnostic market.
• Various opportunities available for the other competitor in the Alzheimer's disease (AD) Diagnostic market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Alzheimer's disease (AD) Diagnostic market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Alzheimer's disease (AD) Diagnostic market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET REPORT STUDY

• Alzheimer's Disease (AD) Diagnostic products providers
• Research organizations and consulting companies
• Alzheimer's Disease (AD) Diagnostic -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Alzheimer's Disease (AD) Diagnostic
• Various end users who want to know more about the Alzheimer's disease (AD) Diagnostic market and latest technological developments in the Alzheimer's disease (AD) Diagnostic market.

FREQUENTLY ASKED QUESTIONS FOR ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

1. What is Alzheimer's Disease (AD) Diagnostic?

The Alzheimer's disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. The devices and tests used to assess memory impairment, thinking skills, functional abilities, behavior changes, and others in order to diagnose the Alzheimer's disease, are known as Alzheimer's disease diagnostic devices.

2. What is the global market for Alzheimer's disease (AD) Diagnostic?

The global Alzheimer's disease (AD) diagnostic market will grow at a CAGR of 10.97% during the forecast period from 2024 to 2030.

3. What are the drivers for global Alzheimer's disease (AD) Diagnostic market?

The Alzheimer's disease (AD) diagnostic market is witnessing a positive market growth owing to the factors such as the rise in the regulatory approvals for Alzheimer's disease (AD) diagnostics, rising prevalence of head injuries, rise in geriatric population, increasing research and development of novel biomarkers, and others will create an exigency for the Alzheimer's disease (AD) Diagnostic market.

4. Who are the key players operating in the global Alzheimer's disease (AD) diagnostic market?

Some of the key market players operating in the Alzheimer's disease (AD) Diagnostic market includes F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN(TM), FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, and others.

5. Which region has the highest share in Alzheimer's disease (AD) Diagnostic market?

Among all the regions, North America is estimated to amass the significant revenue share in the global Alzheimer's disease (AD) Diagnostic market. This can be ascribed to the rising prevalence of head injuries, rise in geriatric population, and the presence of key market players in the region are factors which acts as a supportive factor for the North America Alzheimer's disease (AD) diagnostic market growth.

Table of Contents

1. Alzheimer's Disease (AD) Diagnostic Market Report Introduction

2. Alzheimer's Disease (AD) Diagnostic Market Executive Summary

• 2.1 Scope of the Study
• 2.2 Market at Glance
• 2.3 Competitive Assessment

3. Regulatory Analysis

• 3.1 The United States
• 3.2 Europe
• 3.3 Japan
• 3.4 China

4. Alzheimer's Disease (AD) Diagnostic Market Key Factors Analysis

• 4.1 Alzheimer's Disease (AD) Diagnostic Market Drivers
  • 4.1.1 Rise in the Regulatory Approvals for Alzheimer's Disease (AD) Diagnostics
  • 4.1.2 Rising Prevalence of Head Injuries
  • 4.1.3 Rise in Geriatric Population
  • 4.1.4 Increasing Research and Development of Novel Biomarkers
• 4.2 Alzheimer's Disease (AD) Diagnostic Market Restraints and Challenges
  • 4.2.1 High Cost of Brain Imaging
  • 4.2.2 Due to Stigma and Lack of Awareness
• 4.3 Alzheimer's Disease (AD) Diagnostic Market Opportunities
  • 4.3.1 Increasing Research and Development
  • 4.3.2 Availability of Large Pipeline Diagnostics Products
  • 4.3.3 Development of Non-Invasive Techniques

5. Alzheimer's Disease (AD) Diagnostic Market Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers
• 5.2 Bargaining Power of Consumers
• 5.3 Threat of New Entrants
• 5.4 Threat of Substitutes
• 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Alzheimer's Disease (AD) Diagnostic Market

7. Alzheimer's Disease (AD) Diagnostic Market Layout

• 7.1 By Diagnostics Type
  • 7.1.1 Brain Imaging
    • 7.1.1.1 Computed tomography (CT)
    • 7.1.1.2 Magnetic resonance imaging (MRI)
    • 7.1.1.3 Positron emission tomography (PET)
    • 7.1.1.4 Others
  • 7.1.2 Genetic testing
  • 7.1.3 Blood based tests
  • 7.1.4 Others
• 7.2 By End-User
  • 7.2.1 Hospitals & Clinics
  • 7.2.2 Diagnostic Centers
  • 7.2.3 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.1.2 Canada Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.1.3 Mexico Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
  • 7.3.2 Europe
    • 7.3.2.1 France Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.2.2 Germany Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.2.3 United Kingdom Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.2.4 Italy Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.2.5 Spain Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.2.6 Rest of Europe Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.2 Japan Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.3 India Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.4 Australia Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.5 South Korea Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.6 Russia Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.3.7 Rest of Asia Pacific Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1. Middle East Alzheimer's Disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.4.2 Africa Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)
    • 7.3.4.3 South America Alzheimer's disease (AD) Diagnostic Market in USD million (2021-2030)

8. Alzheimer's Disease (AD) Diagnostic Market Company and Product Profiles

• 8.1 F. Hoffmann-La Roche Ltd.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4 Product Listing
  • 8.1.5. Entropy
• 8.2 General Electric Company
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4 Product Listing
  • 8.2.5. Entropy
• 8.3 23andMe, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4 Product Listing
  • 8.3.5. Entropy
• 8.4 Lilly
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4 Product Listing
  • 8.4.5. Entropy
• 8.5 Fujirebio
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4 Product Listing
  • 8.5.5. Entropy
• 8.6 Siemens Medical Solutions USA, Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4 Product Listing
  • 8.6.5. Entropy
• 8.7 Diadem srl.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4 Product Listing
  • 8.7.5. Entropy
• 8.8 Todos Medical
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4 Product Listing
  • 8.8.5. Entropy
• 8.9 DISCERN(TM)
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5. Entropy
• 8.10 FUJIFILM Holdings America Corporation
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4 Product Listing
  • 8.10.5. Entropy
• 8.11 Koninklijke Philips N.V.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5. Entropy
• 8.12 CANON MEDICAL SYSTEMS EUROPE B.V.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4 Product Listing
  • 8.12.5. Entropy
• 8.13 Shimzadu Corporation.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4 Product Listing
  • 8.13.5. Entropy
• 8.14 Laboratory Corporation of America® Holdings
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4 Product Listing
  • 8.14.5. Entropy
• 8.15 Bruker
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4 Product Listing
  • 8.15.5. Entropy
• 8.16 Magnetica.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4 Product Listing
  • 8.16.5. Entropy
• 8.17 IMRIS, Deerfield Imaging, Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4 Product Listing
  • 8.17.5. Entropy
• 8.18 MR Solutions
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4 Product Listing
  • 8.18.5. Entropy
• 8.19 Hyperfine, Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4 Product Listing
  • 8.19.5. Entropy
• 8.20 Neusoft Corporation
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4 Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us